

CardiacBooster wins second place at the Innovation in Cardiovascular Interventions (ICI) Technology Parade in Tel Aviv, Israel

NEWS PROVIDED BY
CardiacBooster

TEL AVIV, Israel, Dec. 16, 2019 – CardiacBooster, a startup developing the next generation of percutaneous left ventricular assist devices, presented its technology at the 2019 Innovation in Cardiovascular Interventions (ICI) Technology Parade in Tel Aviv. With its novel and patented pump-in-pump technology, which aims to increase cardiac output while unloading the heart, the company won second place.

Cardiogenic shock is a life-threatening medical emergency, with fewer than 60% of patients surviving the first 30 days, despite medical intervention and support by currently available cardiac assist devices. Cardiogenic shock occurs when a heart sustains damage so severe that it is unable to pump blood in sufficient quantity to organs and peripheral tissue. About 5-8% of acute myocardial infarctions (heart attacks) result in cardiogenic shock. These patients are in urgent and immediate need of circulatory support. Existing mechanical assist devices so far have had limited impact on patient (survival) outcomes, although data from newer devices seems to suggest that earlier support with more powerful assist devices may lead to improved survival.

CardiacBooster aims to develop an effective, low profile and low shear stress cardiac assist device. The company's device is expected to support heart function by augmenting stroke volume, thereby helping to maintain and restore the cardiac power output.

“We are thrilled with the recognition by the ICI community” said Florian Ludwig, CEO of CardiacBooster. “CardiacBooster addresses a very attractive market looking for new and improved solutions. We are aiming to serve this market with a novel technology that helps physicians in supporting patients in critical condition.”

“Interventional cardiologists are continuously looking for better ways to support patients' hearts through critical periods” said Daniel van Dort, CSO of CardiacBooster. “CardiacBooster aims to provide physicians with innovative devices that allow strong cardiac support with minimal invasiveness”.

CardiacBooster is seeking investors to accelerate product development, execute a structured pre-clinical program, and execute its clinical program.

About CardiacBooster:

CardiacBooster is developing a novel device to treat patients with severe heart failure. Treatment of such patients focuses on pharmacologic and hemodynamic support of the failing heart. Percutaneous (catheter-based) Ventricular Assist Devices (pVAD's) are already on the market, but the implantation of many of these is associated with a relatively high risk of vascular and access site complications. CardiacBooster's technology is designed to be less invasive while providing strong cardiac support.

Media Contact:

Florian Ludwig, CEO

f.ludwig@cardiacbooster.com